<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>3</td>
</tr>
<tr>
<td>Conditions</td>
<td>4</td>
</tr>
<tr>
<td>Disclaimer</td>
<td>5</td>
</tr>
</tbody>
</table>
Introduction

Coronaviruses are a large family of viruses, some of which cause illness in people, and others that circulate among mammals and birds. Rarely, animal coronaviruses can spread to humans, and then spread between people. Zoonotic coronaviruses have emerged in recent years to cause human outbreaks such as coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).

Illness in humans mainly manifests as a respiratory infection, or sometimes gastrointestinal infection. The clinical spectrum of illness varies from no symptoms or mild respiratory symptoms to severe, rapidly progressive pneumonia, acute respiratory distress syndrome, septic shock, or multi-organ failure resulting in death.
Overview of coronaviruses

Conditions

◊ Coronavirus disease 2019 (COVID-19)

» see our comprehensive coverage of Coronavirus disease 2019 (COVID-19)

An acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in Wuhan City, Hubei Province, China, in December 2019. Since then it has spread to many countries around the world, with the World Health Organization declaring it a pandemic.

◊ Management of co-existing conditions in the context of COVID-19

» see our comprehensive coverage of Management of co-existing conditions in the context of COVID-19

This topic summarises important considerations for the care of people with co-existing medical conditions during the COVID-19 pandemic. Key points from guidance and position statements are summarised for each condition. This overview topic is continually reviewed and updated, and more conditions will be added to this list.

◊ Middle East respiratory syndrome (MERS)

» see our comprehensive coverage of Middle East respiratory syndrome (MERS)

An acute viral respiratory tract infection caused by MERS-CoV. It was first identified in Saudi Arabia in 2012. Cases have been limited to the Arabian Peninsula and its surrounding countries, and to travellers from the Middle East or their contacts. The case fatality rate is approximately 37%.

◊ Severe acute respiratory syndrome (SARS)

» see our comprehensive coverage of Severe acute respiratory syndrome (SARS)

An acute viral respiratory tract infection caused by SARS-CoV. It was first identified in the Guangdong province of Southern China in 2002. The epidemic affected 26 countries and resulted in more than 8000 cases and 774 deaths in 2003. There have been no reported cases since 2004. The case fatality rate is approximately 10%.
Disclaimer

This content is meant for medical professionals situated outside of the United States and Canada. The BMJ Publishing Group Ltd ("BMJ Group") tries to ensure that the information provided is accurate and up-to-date, but we do not warrant that it is nor do our licensors who supply certain content linked to or otherwise accessible from our content. The BMJ Group does not advocate or endorse the use of any drug or therapy contained within nor does it diagnose patients. Medical professionals should use their own professional judgement in using this information and caring for their patients and the information herein should not be considered a substitute for that.

This information is not intended to cover all possible diagnosis methods, treatments, follow up, drugs and any contraindications or side effects. In addition such standards and practices in medicine change as new data become available, and you should consult a variety of sources. We strongly recommend that users independently verify specified diagnosis, treatments and follow up and ensure it is appropriate for your patient within your region. In addition, with respect to prescription medication, you are advised to check the product information sheet accompanying each drug to verify conditions of use and identify any changes in dosage schedule or contraindications, particularly if the agent to be administered is new, infrequently used, or has a narrow therapeutic range. You must always check that drugs referenced are licensed for the specified use and at the specified doses in your region. This information is provided on an "as is" basis and to the fullest extent permitted by law the BMJ Group and its licensors assume no responsibility for any aspect of healthcare administered with the aid of this information or any other use of this information.

View our full Website Terms and Conditions.

Contact us
+ 44 (0) 207 111 1105
support@bmj.com

BMJ
BMA House
Tavistock Square
London
WC1H 9JR
UK

5